A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after progression on prior systemic chemotherapy
- Registry ID
- EUCTR2008-006544-20
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Novartis Pharma Services AG
- Start date
- 2009-05-18
- Last update
- 2026-08-16
Conditions
- advanced gastric cancer
- cáncer gástrico avanzado
Summary
To compare overall survival between RAD001+best supportive care (BSC) and placebo+BSC in patients with advanced gastric cancer after progression on prior systemic chemotherapy.
Locations
- , , UK
- , , Spain
- , , Italy
- , , Germany
- , , France
- , , Netherlands
- , , Belgium
View on source registry